Wikidata entity: Q191521
C₂₂H₃₀N₆O₄S (P274)
Quantities
| P4250 | defined daily dose | 50 |
| P2067 | mass | 474.20492444000007 |
| P3780 | active ingredient in | ... | Q29006316 (Patrex) | Patrex |
| P3780 | active ingredient in | ... | Q29006431 (Revatio) | Revatio |
| P3780 | active ingredient in | ... | Q29006481 (Sildenafil Actavis) | Sildenafil Actavis |
| P3780 | active ingredient in | ... | Q29006482 (Sildenafil Ratiopharm) | Sildenafil Ratiopharm |
| P3780 | active ingredient in | ... | Q29006483 (Sildenafil Teva) | Sildenafil Teva |
| P3780 | active ingredient in | ... | Q29006643 (Viagra) | Viagra |
| P3780 | active ingredient in | ... | Q29006665 (Vizarsin) | Vizarsin |
| P233 | canonical SMILES | String | CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C | ??? |
| P373 | Commons category | String | Sildenafil | ??? |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P527 | has part(s) | ... | Q682 (sulfur) | sulfur |
| P527 | has part(s) | ... | Q556 (hydrogen) | hydrogen |
| P527 | has part(s) | ... | Q629 (oxygen) | oxygen |
| P366 | has use | ... | Q3591110 (lifestyle drug) | lifestyle drug |
| P366 | has use | ... | Q12140 (medication) | medication |
| P8224 | image of molecular model or crystal lattice model | CommonsMedia | http://commons.wikimedia.org/wiki/Special:FilePath/Sildenafil-from-xtal-3D-balls.png | ??? |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P8026 | LiverTox likelihood score | ... | Q83284310 (LiverTox toxicity likelihood category C) | LiverTox toxicity likelihood category C |
| P2175 | medical condition treated | ... | Q1128595 (pulmonary hypertension) | pulmonary hypertension |
| P2175 | medical condition treated | ... | Q184674 (erectile dysfunction) | erectile dysfunction |
| P2175 | medical condition treated | ... | Q18556468 (vasculogenic impotence) | vasculogenic impotence |
| P129 | physically interacts with | ... | Q21118791 (ATP binding cassette subfamily C member 5) | ATP binding cassette subfamily C member 5 |
| P129 | physically interacts with | ... | Q21123239 (Phosphodiesterase 6C) | Phosphodiesterase 6C |
| P129 | physically interacts with | ... | Q21125248 (solute carrier organic anion transporter family member 1B3) | solute carrier organic anion transporter family member 1B3 |
| P129 | physically interacts with | ... | Q21136123 (Solute carrier organic anion transporter family member 2B1) | Solute carrier organic anion transporter family member 2B1 |
| P129 | physically interacts with | ... | Q410798 (Phosphodiesterase 5A) | Phosphodiesterase 5A |
| P3489 | pregnancy category | ... | Q3679232 (Australian pregnancy category B1) | Australian pregnancy category B1 |
| P3489 | pregnancy category | ... | Q28123616 (US pregnancy category B) | US pregnancy category B |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q162867 (nitroglycerin) | nitroglycerin |
| P769 | significant drug interaction | ... | Q118551 (clarithromycin) | clarithromycin |
| P769 | significant drug interaction | ... | Q418130 (nebivolol) | nebivolol |
| P769 | significant drug interaction | ... | Q418480 (tamsulosin) | tamsulosin |
| P769 | significant drug interaction | ... | Q419939 (doxazosin) | doxazosin |
| P769 | significant drug interaction | ... | Q425296 (prazosin) | prazosin |
| P769 | significant drug interaction | ... | Q1243800 (isosorbide) | isosorbide |
| P769 | significant drug interaction | ... | Q2154494 (riociguat) | riociguat |
| P769 | significant drug interaction | ... | Q2736873 (alfuzosin) | alfuzosin |
| P769 | significant drug interaction | ... | Q5138908 (cobicistat) | cobicistat |
| P769 | significant drug interaction | ... | Q179748 (isosorbide dinitrate) | isosorbide dinitrate |
| P769 | significant drug interaction | ... | Q213511 (erythromycin) | erythromycin |
| P769 | significant drug interaction | ... | Q280786 (terazosin) | terazosin |
| P769 | significant drug interaction | ... | Q388801 (furosemide) | furosemide |
| P769 | significant drug interaction | ... | Q407883 (ketoconazole) | ketoconazole |
| P769 | significant drug interaction | ... | Q412236 (voriconazole) | voriconazole |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q424153 (PDE5 inhibitor) | PDE5 inhibitor |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | sildenafil | ??? |
Why not click here or view trends?
log id: 2730457